Table 2.
SF+ samples are positively corrected with CNA 7p10q, CLA and IGS-18 subtype and IDH1-WT tumors
| Group |
||||
|---|---|---|---|---|
| SF− | SFnp | SF+ | P | |
| n = 12 | n = 15 | n = 19 | ||
| TCGA | ||||
| ND | 1 | 2 | 2 | |
| CLA | 2 | 3 | 11 | .0086 |
| MES | 2 | 2 | 2 | |
| NEU | 1 | 2 | 2 | |
| PRO | 6 | 6 | 2 | .0183 |
| IGS | ||||
| ND | 1 | 2 | 2 | |
| 16 | 0 | 0 | 1 | |
| 17 | 3 | 6 | 3 | .296 |
| 18 | 3 | 1 | 10 | .0078 |
| 22 | 1 | 0 | 0 | |
| 23 | 1 | 3 | 3 | |
| 9 | 3 | 3 | 0 | .032 |
| IDH | ||||
| MUT | 7 | 6 | 0 | .00021 |
| WT | 5 | 9 | 19 | |
| 1p19q loss | ||||
| ND | 4 | 2 | 8 | |
| Loss | 4 | 3 | 0 | .066 |
| NC | 4 | 10 | 11 | |
| Chr7p10q | ||||
| ND | 6 | 10 | 8 | |
| Normal | 5 | 4 | 0 | |
| Present | 1 | 1 | 11 | .00022 |
| EGFR | ||||
| ND | 6 | 10 | 8 | |
| n < 4 | 5 | 3 | 7 | |
| n > 4 | 1 | 2 | 4 | |
| CDKN2A/B | ||||
| ND | 6 | 10 | 8 | |
| NC | 3 | 3 | 2 | |
| n < 2 | 3 | 2 | 9 | .18 |
Table illustrates an overview of the distribution of previously identified driver alterations and subtypes associated with glioma. Significance levels are derived from Fishers exact test–based comparison between SF+ vs SF−/SFnp combined cohort. Abbreviations (for group names similar to Table 1): ND, not determined; NC, no change; MES, mesenchymal; NEU, neuronal; PRO, proneural; CLA, classical. 1p19q signifies the combined loss of chromosome 1p and 19q. Chr7p10q, the combined gain of 7p and loss of 10q.